Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review.

Date publication

juillet 2021

Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie , Mme POZET Astrid , Dr MOUILLET Guillaume , Mr FALCOZ Antoine

Tous les auteurs :
Anota A, Pozet A, Lemasson H, Cotté FE, Falcoz A, Eberst G, Mouillet G, Guerzider S, Charton É, Westeel V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34283382

Résumé

A systematic literature review of immuno-oncology trials was conducted to assess the potential impact of open-label vs double-blind trial design on patient-reported outcome (PRO) data.

Mots clés

Bias, Immuno-oncology, Open label, Patient-reported outcomes, Quality of life, Randomized controlled trials

Référence

Qual Life Res. 2021 Jul 20;: